AVS Pulse Intravascular Lithotripsy™ (Pulse IVL™) to Open Vessels With Calcific Walls and Enhance Vascular Compliance and Remodeling for Coronary Artery Disease
Condition(s) studied
Investigational drug(s) / intervention(s)
Pulse Intravascular Lithotripsy (Pulse IVL): The Pulse Intravascular Lithotripsy (Pulse IVL) System is used for the treatment of severely calcified stenotic de novo coronary arteries prior to stenting in patients with coronary artery disease.
Study summary
A prospective, open-label, multi-site, FIH with up to fifteen (n=15) patients to assess the safety and preliminary effectiveness of the AVS Pulse Intravascular Lithotripsy™ System (Pulse IVL™ System) when used for the treatment of coronary artery disease.
Eligibility
Primary outcome measure(s)
- Achieve residual stenosis (<50%) in conjunction with stenting in the absence of major device related adverse events — Completion of study procedure
- Target lesion failure (TLF) — Within 30 days of study procedure
Trial sites (3)
| Facility | City | Region | Status |
|---|---|---|---|
| St. Vincent's Hospital | Sydney | New South Wales | Recruiting |
| Monash Health, Victorian Heart Hospital | Melbourne | Victoria | Recruiting |
| Auckland City Hospital | Auckland | New Zealand | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07510438 on ClinicalTrials.gov ↗ ← All trials in Australia